← All trials
NCT04515186
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 9, 2020
- Primary completion
- Jun 30, 2022
- Completion date
- Mar 30, 2023
- First posted
- Aug 17, 2020
- Last posted
- Aug 17, 2020
- Enrollment
- 306
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Drugs for Neglected Diseases InitiativeLead sponsor
- Federal University of BahiaOverall official - principal investigator
- Cayetano Heredia UniversityOverall official - principal investigator
- Fundacion Nacional de DermatologiaOverall official - principal investigator
- Federal University of Mato Grosso do SulOverall official - principal investigator
- Instituto Conmemorativo Gorgas de Estudios de la SaludOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.